Drug Trial Radar · NCT06304805
TGRX-326 Pharmacokinetic Food Effect Bioavailability Study
Last checked: Nov 19, 2026Latest source record: May 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Dec 13, 2023
Primary completion
Jan 12, 2024
Study completion Jan 19, 2024
Sponsor
- Lead sponsor
- Shenzhen TargetRx Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- The First Affiliated Hospital of Bengbu Medical University
- First posted
- Mar 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A study evaluating the effects of food intake on the pharmacokinetic (PK) profiles of TGRX-326 and the effect of different drug specifications on human bioavailability for TGRX-326, a drug indicated for non-small cell lung cancer treatment
Conditions
- Non Small Cell Lung Cancer
Interventions
cycle 1: treatment drugDrug
for cycle 1 treatment: participants are given the oral treatment specification (60 mg \*1 pill)
cycle 1: reference drugDrug
for cycle 1 treatment: participants are given the oral reference specification (5 mg \*2 pills + 25 mg \* 2 pills)
cycle 1: fastedBehavioral
for cycle 1 treatment: participants are asked to take the drug fasted
cycle 1: foodBehavioral
for cycle 1 treatment: participants are asked to take the drug after food intake
cycle 2: treatment drugDrug
for cycle 2 treatment: participants are given the oral treatment specification (60 mg \*1 pill)
cycle 2: reference drugDrug
for cycle 2 treatment: participants are given the oral reference specification (5 mg \*2 pills + 25 mg \* 2 pills)
cycle 2: fastedBehavioral
for cycle 2 treatment: participants are asked to take the drug fasted
cycle 2: foodBehavioral
for cycle 2 treatment: participants are asked to take the drug after food intake
cycle 3: treatment drugDrug
for cycle 3 treatment: participants are given the oral treatment specification (60 mg \*1 pill)
cycle 3: reference drugDrug
for cycle 3 treatment: participants are given the oral reference specification (5 mg \*2 pills + 25 mg \* 2 pills)
cycle 3: fastedBehavioral
for cycle 3 treatment: participants are asked to take the drug fasted
cycle 3: foodBehavioral
for cycle 3 treatment: participants are asked to take the drug after food intake
Primary outcomes
What the sponsor says the trial is designed to measure.
- Plasma CmaxTime frame: During treatment period on Day 1 of each of three cycles (each cycle is one day, and there is a 10-day washout period between two cycles)
- Plasma AUC(0-t)Time frame: During treatment period on Day 1 of each of three cycles (each cycle is one day, and there is a 10-day washout period between two cycles)
- Plasma AUC(0-inf)Time frame: During treatment period on Day 1 of each of three cycles (each cycle is one day, and there is a 10-day washout period between two cycles)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
First Affiliated Hospital Bengbu Medical College
Bengbu, Anhui, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.